Ethinylestradiol/drospirenone: similar VTE risk to other combined OCs

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2004年 / 1028卷 / 1期

关键词：

Cohort Study; Oral Contraceptive; Venous Thromboembolism; Current Problem; Monitoring Study;

D O I：

10.2165/00128415-200410280-00001

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 24 条

[1] No extra VTE risk with 24-day ethinylestradiol/drospirenone
Reactions Weekly, 2010, 1326 (1) : 3 - 3
[2] Drospirenone-containing OCs under review for VTE
Reactions Weekly, 2011, 1355 (1) : 2 - 2
[3] Ethinylestradiol/cyproterone and VTE: who is at risk?
Reactions Weekly, 2004, 1016 (1) : 4 - 4
[4] Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives
Loughlin, Jeanne
Seeger, John D.
Eng, P. Mona
Foegh, Marie
Clifford, C. Robin
Cutone, Jennifer
Walker, Alexander M.
CONTRACEPTION, 2008, 78 (05) : 377 - 383
[5] Low-dose estrogen combined OCs increase VTE risk
Reactions Weekly, 2004, 1014 (1) : 5 - 5
[6] Does current methodology overestimate the risk of VTE with OCs?
Reactions Weekly, 2002, 908 (1) : 4 - 4
[7] Increased VTE risk with OCs due to residual confounding
Reactions Weekly, 1997, 634 (1) : 3 - 3
[8] Increased VTE risk of third-generation OCs not supported
Reactions Weekly, 2000, 816 (1) : 5 - 5
[9] Drospirenone ups risk of VTE, PE, but not TIA, stroke
Reactions Weekly, 2011, 1382 (1) : 2 - 2
[10] `Third-generation' OCs and VTE: biases could explain the increased risk
Reactions Weekly, 1997, 635 (1) : 3 - 3